Oncocyte Corporation (OCX) ニュース

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics...

Form 4 - Statement of changes in beneficial ownership of securities

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology...

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms 

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes...

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form S-3 - Registration statement under Securities Act of 1933

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities